Eliem Therapeutics Inc
NASDAQ:ELYM
Eliem Therapeutics Inc
Short-Term Investments
Eliem Therapeutics Inc
Short-Term Investments Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Short-Term Investments | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Eliem Therapeutics Inc
NASDAQ:ELYM
|
Short-Term Investments
$13.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Abbvie Inc
NYSE:ABBV
|
Short-Term Investments
$28m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
12%
|
||
Gilead Sciences Inc
NASDAQ:GILD
|
Short-Term Investments
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Amgen Inc
NASDAQ:AMGN
|
Short-Term Investments
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Short-Term Investments
$1.3B
|
CAGR 3-Years
23%
|
CAGR 5-Years
17%
|
CAGR 10-Years
5%
|
||
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Short-Term Investments
$7.8B
|
CAGR 3-Years
49%
|
CAGR 5-Years
39%
|
CAGR 10-Years
35%
|
Eliem Therapeutics Inc
Glance View
Eliem Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company is headquartered in Redmond, Washington and currently employs 19 full-time employees. The company went IPO on 2021-08-10. The firm focuses on developing novel therapies for neuronal excitability disorders that addresses unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the perishable and central nervous system. The firm offers two lead clinical-stage candidates: ETX-810 and ETX-155. ETX-810 is a palmitoylethanolamide (PEA) prodrug developed for the treatment of diabetic peripheral neuropathic pain (DPNP) and pain associated with lumbosacral radiculopathy (LSRP). ETX-810 is being evaluated in two Phase II a clinical trial. ETX-155 is a neurosteroid gamma-aminobutyric acid type A (GABAA) receptor positive allosteric modulator (PAM) developed for major depressive disorder (MDD), perimenopausal depression (PMD) and focal onset seizures (FOS). The firm provides two programs in addition to its clinical candidates, namely Kv7.2/3 program and anxiolytic.
See Also
What is Eliem Therapeutics Inc's Short-Term Investments?
Short-Term Investments
13.7m
USD
Based on the financial report for Dec 31, 2023, Eliem Therapeutics Inc's Short-Term Investments amounts to 13.7m USD.
What is Eliem Therapeutics Inc's Short-Term Investments growth rate?
Short-Term Investments CAGR 1Y
-83%
Over the last year, the Short-Term Investments growth was -83%.